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Case-control studies generally suggesting an inverse association between sun exposure and non-Hodgkin
lymphoma (NHL) have led to speculation that vitamin D may protect against lymphomagenesis. To examine this
hypothesis, the authors conducted a pooled investigation of circulating 25-hydroxyvitamin D (25(OH)D) and sub-
sequent NHL risk within 10 cohorts participating in the Cohort Consortium Vitamin D Pooling Project of Rarer
Cancers. The authors analyzed measurements from 1,353 cases and 1,778 controls using conditional logistic
regression and other methods to estimate the association of 25(OH)D with NHL. No clear evidence of association
between categories of25(OH)DconcentrationandNHL wasobservedoverall(Ptrend¼ 0.68)orbysex (men,Ptrend¼
0.50; women, Ptrend ¼ 0.16). Findings for other measures (continuous log(25(OH)D), categories of 25(OH)D using
sex-/cohort-/season-speciﬁc quartiles as cutpoints, categories of season-adjusted residuals of predicted 25(OH)D
using quartiles as cutpoints) were generally null, although some measures of increasing 25(OH)D were suggestive
of an increased risk for women. Results from stratiﬁed analyses and investigations of histologic subtypes of NHL
were also null. These ﬁndings do not support the hypothesis that elevated circulating 25(OH)D concentration is
associated with a reduced risk of NHL. Future research investigating the biologic basis for the sunlight–NHL
association should consider alternative mechanisms, such as immunologic effects.
calcifediol; calcitrol; case-control studies; cohort studies; 25-hydroxyvitamin D 2; lymphoma, non-Hodgkin;
prospective studies; vitamin D
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CLL/SLL, chronic lymphocytic leukemia/
small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; ICD-O-2/3, International Classiﬁcation of Diseases for
Oncology, Second/Third Edition; NHL, non-Hodgkin lymphoma; NIST, National Institute of Standards and Technology;
25(OH)D, 25-hydroxyvitamin D; VDPP, Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
Epidemiologic ﬁndings generally suggest that exposure to
solar ultraviolet radiation may be associated with a reduced
risk of non-Hodgkin lymphoma (NHL) (1). Increasing am-
bient ultraviolet radiation levels (or, as a proxy, decreasing
latitude) have been associated with decreasing NHL inci-
dence or mortality rates in the United States and some parts
of Europe (2–5), although conﬂicting ecologic ﬁndings have
also been reported (6–8). Several case-control studies from
Australia, Europe, and the United States have also observed
decreasing risks of NHL with increasing self-reported life-
time sun exposure (9–14), although an association with in-
creased NHL risk was observed in a US population-based
58 Am J Epidemiol 2010;172:58–69case-control study (15). In a pooled analysis involving 10
case-control studies participating in the International Lym-
phoma Epidemiology (InterLymph) Consortium, a reduction
in NHL risk was observed for high recreational sun exposure
at 18–40 years of age and in the 10 years before diagnosis for
B-cell, but not T-cell, lymphomas (16). The pooled ﬁndings
demonstrated a dose-response relation with amount of recre-
ational ultraviolet radiation exposure; however, the magni-
tude of the association was weak, with a 25% reduction in
risk for the highest quartile of exposure versus the lowest.
A plausible mechanism postulated for the observed pro-
tective association between ultraviolet radiation exposure
and NHL risk is that of ultraviolet radiation–induced sub-
cutaneous synthesis of vitamin D, a steroid prohormone
with antineoplastic properties (17). The vitamin D receptor,
through which vitamin D effects are mediated, is expressed
in activated B- and T-lymphocytes (18, 19). Lymphocytes
also express 1a-hydroxylase, the enzyme responsible for
converting the major circulating form of vitamin D (25-
hydroxyvitamin D (25(OH)D)) into its bioactive metabolite
(1,25-dihydrovyvitamin D) (20). Vitamin D has been re-
ported to inhibit proliferation and induce differentiation in
lymphocytes (19) and lymphoma cell lines (21). In an early-
phase clinical trial of the vitamin D analog alpha-calcidol,
24% of 34 treated patients with progressive low-grade lym-
phoma experienced tumor regression (22).
Prospective cohorts with biospecimen banks enable in-
vestigation of prediagnostic circulating 25(OH)D concen-
trations in people subsequently diagnosed with NHL
relative to their peers. In the only such study published to
date to our knowledge, serum concentrations of 25(OH)D
were associated with a decreased risk of NHL diagnosed
within the ﬁrst 7 years of blood collection, butnot thereafter,
in a cohort of male Finnish smokers (23). In light of the
study’s small size and unique population, there is a clear
need for additional epidemiologic studies to address the
hypothesis that the vitamin D pathway inhibits lymphoma-
genesis. Ideally, such studies would be large enough to en-
able exploration of possible heterogeneity in 25(OH)D
effects across NHL histologic subtypes and draw from pop-
ulations spanning a wide range of latitudes to ensure broad
variation in 25(OH)D levels.
With this goal in mind, the Vitamin D Pooling Project of
Rarer Cancers (VDPP) was developed within the Cohort
Consortium sponsored by the National Cancer Institute to
examine the relation between circulating 25(OH)D levels
and risk of NHL and other rarer malignancies (cancers of
the endometrium, ovary, kidney, pancreas, and upper gas-
trointestinal tract). This article reports ﬁndings from the
pooled investigation of NHL, which included 1,353 cases
and 1,778 controls selected from 10 cohort studies con-
ducted in the United States (n ¼ 7), Finland (n ¼ 1), and
Shanghai, China (n ¼ 2).
MATERIALS AND METHODS
Study design and population
A detailed description of the design of the VDPP is pro-
vided elsewhere in this issue of the Journal (24). Ten par-
ticipating cohorts contributed plasma or serum toward the
pooled investigation of NHL (Table 1). A nested case-
controldesign wasused, anda sample ofsubjectswithstored
serum or plasma specimens who were cancer free at the
time of blood collection was selected from each cohort.
Incident cases included NHL (International Classiﬁcation
of Diseases for Oncology, Second Edition (ICD-O-2) codes
9591–9593, 9595, 9670–9677, 9680–9688, 9690–9698,
Table 1. Characteristics of Participants, by Cohort, in the Investigation of Non-Hodgkin Lymphoma Within the
Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
Cohort No. of
Cases
No. of
Controls
Median Years From Blood
Collection to Cancer
Diagnosis (Interquartile Range)
Median Circulating 25(OH)D, nmol/L
(Interquartile Range)
Cases Controls
ATBC 208 531 7.5 (4.2–10.9) 46.1 (35.3–62.9) 48.0 (35.3–64.5)
CLUE 236 252 10.4 (6.0–14.5) 60.2 (45.1–78.0) 57.3 (43.8–73.7)
CPS-II 135 141 2.5 (1.4–3.6) 58.7 (46.6–76.4) 60.3 (49.0–78.4)
HPFS 133 147 4.4 (2.6–6.7) 58.7 (44.8–70.3) 58.6 (45.8–76.6)
MEC 96 101 1.9 (0.7–3.3) 55.4 (40.2–67.7) 52.4 (40.3–66.0)
NHS 145 145 5.8 (4.4–8.6) 55.3 (38.5–72.2) 56.3 (45.0–70.5)
NYU-WHS 73 101 9.2 (5.9–12.6) 49.5 (37.1–63.6) 51.2 (34.9–65.4)
PLCO 286 296 5.0 (2.8–7.0) 56.0 (44.3–68.4) 53.8 (40.1–65.6)
SMHS 8 12 1.5 (0.7–2.3) 46.8 (32.0–57.1) 39.4 (22.5–65.7)
SWHS 33 52 3.5 (1.0–6.7) 32.2 (22.5–45.9) 30.7 (23.0–49.2)
Total 1,353 1,778 5.2 (2.5–8.7) 55.7 (40.6–70.1) 53.5 (38.8–68.8)
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II, Cancer Prevention
Study II Nutrition Cohort; HPFS, Health Professionals Follow-Up Study; MEC, The Multiethnic Cohort Study; NHS,
Nurses’ Health Study; NYU-WHS, New York University Women’s Health Study; 25(OH)D, 25-hydroxyvitamin D;
PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SMHS, Shanghai Men’s Health Study;
SWHS, Shanghai Women’s Health Study.
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Am J Epidemiol 2010;172:58–699700–9717, 9760–9762, 9764, 9821, 9823, 9825–9828,
9940, 9941; International Classiﬁcation of Diseases for
Oncology, Third Edition (ICD-O-3) codes 9591–9593,
9595, 9596, 9670, 9671, 9673, 9675, 9678–9680, 9684,
9687, 9689–9691, 9695, 9698–9702, 9705, 9708, 9709,
9714, 9716–9719, 9727–9729, 9761, 9762, 9823, 9825,
9827, 9831–9837, 9940, 9948) and other rare or unclassiﬁed
lymphoid malignancies (ICD-O-2 codes 9590, 9594, 9731,
9820, 9822, 9824, 9850; ICD-O-3 codes 9590, 9594, 9731,
9734, 9820, 9970). Cases of Hodgkin lymphoma (ICD-O-2
and ICD-O-3 codes 9650–9667) were also included by the
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
(ATBC) and cases of multiple myeloma (ICD-O-2 code
9732; ICD-O-3 codes 9732, 9733) by ATBC and the New
York University Women’s Health Study. To focus on NHL as
an endpoint, non-NHL cases have been excluded from the
ﬁnal results presented here; however, their inclusion yielded
virtually identical ﬁndings. The median time from blood
collection to diagnosis of NHL cases was 5.2 years, with
a range of <0.1–31.6 years.
Controls were individually matched to cases (1:1 ratio)
from among individuals who were alive and cancer free at
the time of case diagnosis; matching was performed on the
basis of age at blood collection (61 year), sex, race/ethnicity
(white, black, Asian, other), and date of blood draw (630
days). The Shanghai Women’s Health Study additionally
matched on menopausal status for women. Different control
selection schemes were used by 2 cohorts whose study sam-
ples were drawn prior to VDPP. Within ATBC, 2 controls
were matched to each case by birth year and month of base-
lineblooddrawfromamongindividualswhowerelymphoma
free at case diagnosis. In the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial, one control was matched to
eachcasebyageatbaseline(5-yearcategories),sex,race,and
date of baseline blood draw (3-month categories) from
among individuals who were cancer free at case diagnosis.
Measurement of circulating 25(OH)D
Concentrations of 25(OH)D in 125-lL samples of serum
or plasma were measured at Heartland Assays, Inc. (Ames,
Iowa)usingadirect, competitivechemiluminescenceimmu-
noassay (DiaSorin LIAISON 25 OH Vitamin D TOTAL as-
say; DiaSorin Inc., Stillwater, Minnesota) (25). Assays were
performed in cohort-speciﬁc batches of as many as 100 sam-
ples, with several types of masked reference samples used to
assess quality control. Each cohort was provided with sam-
ples of the vitamin D standard (Standard Reference Material
972 Vitamin D in Human Serum) from the National Institute
of Standards and Technology (NIST) at both level 1 (~60
nmol/L) and level 2 (~35 nmol/L) to include with their sam-
ples, as described by Gallicchio etal. (24). In addition, 2or 4
masked quality control samples from each cohort were in-
cluded in each batch of their samples.
Coefﬁcients of variation for duplicate serum/plasma ali-
quots included in all laboratory sample batches were calcu-
lated by using the variance components model of SAS
software (PROC VARCOMP; SAS Institute, Inc., Cary,
North Carolina) for the 3 types of quality control samples:
NIST level 1, NIST level 2, and each cohort quality control.
Interbatch and intrabatch coefﬁcients of variation for NIST
level 1 samples were 12.7% and 9.3%, respectively; inter-
batch and intrabatch coefﬁcients of variation for NIST level
2 samples were 13.6% and 11.0%, respectively. The median
interbatch coefﬁcient of variation for the cohort quality con-
trol samples was 13.2% (range: 4.8–17.0); the median intra-
batch coefﬁcient of variation for the cohort quality control
samples was 9.9% (range: 3.8–16.4). The majority of ATBC
samples (189 of 208 cases, 506 of 531 controls) were
assayed prior to VDPP by the same laboratory (interbatch
coefﬁcient of variation, 14.0%).
Statistical analysis
Statistical analyses were performed by using SAS soft-
ware, versions 9.1.3 and 9.2 (SAS Institute, Inc.). The
analytic strategy for VDPP is outlined in greater detail
elsewhere (24). The distributions of several subject charac-
teristics were compared between NHL cases and their
matched controls by using Wald test statistics computed
from simple conditional logistic regression models; this
approach was used in favor of bivariate statistics (e.g.,
Pearson chi-square and Wilcoxon rank-sum tests) to ac-
count for the difference in case:control ratio between ATBC
(1:2) and the other cohorts (1:1). All reported P values are
2-sided.
For the main analysis, 25(OH)D was analyzed as a cate-
gorical variable, with measurements divided into 6 catego-
ries by using clinically relevant cutpoints (<25, 25–<37.5,
37.5–<50, 50–<75, 75–<100, and  100 nmol/L) deﬁned
following a review of the literature (26–28). Analyses were
also conducted by using the natural log of 25(OH)D as a con-
tinuous variable; the log-transformation was performed be-
cause of the right-skewed nature of the original 25(OH)D
distribution. Two additional approaches for categorizing
25(OH)Dwereusedtoadjustfortheknownseasonalvariation
in 25(OH)D. In the ﬁrst method, 25(OH)D measurements
were categorized onthebasis oftheir distributionwithin a par-
ticular stratum of cohort, sex, and season of blood collection,
with stratum-speciﬁc quartiles among VDPP controls used as
cutpoints.(Asimilarapproachinvolvingonlysex-andseason-
speciﬁc strata yielded virtually identical results, which are not
presented in this paper.) In the second method, the residuals
were calculated from locally weighted scatter plot smoothing
(loess) models regressing 25(OH)D onto week of blood draw
stratiﬁed by gender and cohort (24). The residuals were cate-
gorized into quartiles based on the distributions within each
sex- and cohort-speciﬁc stratum.
The association between 25(OH)D variables and NHL
risk within the combined data set was evaluated by comput-
ing odds ratios and 95% conﬁdence intervals with condi-
tional logistic regression. Tests for trend of the categorical
25(OH)D variables were performed by using a Wald test
statistic after assigning ordinal scores (0, 1, 2, 3, ...)t o
the categories and modeling the variable as a continuous
parameter. Alcohol consumption, education, body mass
index, height, and hormone replacement therapy were as-
sessed as potential confounding factors. Additional model
adjustment for height ( 165, >165–171, >171–178,
and >178 cm) was found to change odds ratio magnitudes
60 Purdue et al.
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Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
Characteristic
Cases (N 5 1,353) Controls (N 5 1,778)
a
P Value
b
No. % Median
(Interquartile Range) No. % Median
(Interquartile Range)
Age at blood
collection, years
62 (56–68) 61 (55–67) Matched
Sex Matched
Male 762 56.3 1,127 63.4
Female 591 43.7 651 36.6
Race Matched
White 1,191 88.0 1,572 88.4
Black 38 2.8 50 2.8
Asian 72 5.3 99 5.6
Other 42 3.1 41 2.3
Missing 10 0.7 16 0.9
Season of blood collection Matched
Winter 289 21.4 441 24.8
Spring 327 24.2 420 23.6
Summer 384 28.4 452 25.4
Fall 353 26.1 465 26.2
Height, cm 170.2 (163.0–177.8) 171.0 (165.0–177.8) 0.03
Body mass index, kg/m
2 0.29
<25 523 38.7 699 39.3
25–<30 484 35.8 696 39.1
 30 232 17.1 252 14.2
Missing 114 8.4 131 7.4
Education 0.29
Less than high school 215 15.9 359 20.2
Completed high school 221 16.3 267 15.0
Vocational school 134 9.9 276 15.5
Some college 317 23.4 400 22.5
College graduate 167 12.3 177 10.0
Graduate studies 282 20.8 284 16.0
Missing 17 1.3 15 0.8
Alcohol consumption,
g ethanol/day
1.9 (0–11.7) 2.8 (0–14.6) 0.69
Dietary energy intake,
kcal/day
1,828 (1,441–2,436) 1,992 (1,510–2,605) 0.82
Energy-adjusted dietary
vitamin D, IU/day
188 (127–288) 178 (125–263) 0.43
Histologic subtype
DLBCL 344 25.4
FL 206 15.2
CLL/SLL 401 29.6
Other/NOS 402 29.7
Circulating 25(OH)D,
nmol/L
55.7 (40.6–70.1) 53.5 (38.8–68.8) 0.65
Abbreviations: CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell
lymphoma; FL, follicular lymphoma; NOS, not otherwise speciﬁed; 25(OH)D, 25-hydroxyvitamin D.
a The number of controls is larger than the number of non-Hodgkin lymphoma cases because 1) 1 cohort (the
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC)) selected 2 controls per case, and 2) 2 cohorts
(ATBC and the New York University Women’s Health Study) included a small number of lymphoma cases other than
non-Hodgkin lymphoma, which were later excluded from analysis.
b Test of independence between variable and case-control status; performed by using the Wald test from condi-
tional logistic regression.
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sequently, height was included as a covariate in the reported
results. Study-speciﬁc odds ratio estimates for the
25(OH)D categories of <25 nmol/L and  100 nmol/L
(vs. 50–75 nmol/L) were summarized by using forest plots.
Included in each forest plot was a summary odds ratio esti-
mate calculated by meta-analysis using a random-effects
model and a test of between-study odds ratio heterogeneity
using the Q statistic. Forest plots and meta-analyses were
conducted by using the R function MiMa (29). Sensitivity
analyses were performed by excluding each study from
the analysis to assess the extent to which the pooled results
were inﬂuenced by each individual study.
Stratiﬁed analyses were conducted for several factors:
sex, age (<60 years,  60 years), season of blood collec-
tion (June 1–November 30, December 1–May 31), lati-
tude (<35 N, 35 –42 N, >42 N), body mass index
(<25, 25–<30,  30 kg/m
2), use of calcium supplements
(no current use, current use), physical activity (sedentary,
light, moderate, vigorous), female hormone replacement
therapy use at questionnaire administration (yes, no), and
length of follow-up until case diagnosis (<5 years,  5
years). Analyses restricted to white subjects only and to
US cohorts only were also performed. Conditional logis-
tic regression models were used when the matched sets
were retained after stratiﬁcation (sex, length of follow-up
until case diagnosis, restriction to white subjects, restric-
tion to US cohorts). Unconditional regression models,
additionally adjusted for cohort, age, sex, race, and season
of blood collection, were used for the remaining stratiﬁed
analyses because odds ratio estimates were essentially
identical to those generated from conditional models,
but 95% conﬁdence intervals were narrower because more
case-control matches were retained. Tests of interaction
between 25(OH)D measures and each stratiﬁcation factor
were performed by using the likelihood ratio test.
Analyses for speciﬁc histologically deﬁned NHL sub-
types were also conducted (diffuse large B-cell lymphoma
(DLBCL), follicular lymphoma, chronic lymphocytic leu-
kemia/small lymphocytic lymphoma (CLL/SLL), other/not
otherwise speciﬁed). Polytomous regression was used to
explore possible heterogeneity in the effect of 25(OH)D
on the common subtypes.
RESULTS
The distributions of selected characteristics among cases
and controls are summarized in Table 2. The majority of
subjects were white (88% of cases, 88% of controls), with
a slight excess of men compared with women (men: 56% of
cases, 63% of controls; the difference between cases and
controls is due to the 2:1 matching ratio in ATBC). The
median age at blood collection was 61 years (62 years for
cases, 61 years for controls), with blood collection dates
distributed evenly across winter, spring, summer, and fall.
Cases and controls were generally comparable with respect
to these and other characteristics, with the exception
of height, for which a small, but statistically signiﬁcant
difference was reported (median: cases, 170.2 cm; controls,
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Am J Epidemiol 2010;172:58–69171.0 cm; P ¼ 0.03). Twenty-ﬁvepercent of cases of disease
were histologically classiﬁed as DLBCL, 15% as follicular
lymphoma, 30% as CLL/SLL, and 30% as other or not
otherwise speciﬁed histology.
The median concentrations of measured 25(OH)D among
the cases and controls were 55.7 nmol/L and 53.5 nmol/L,
respectively (P ¼ 0.65). Table 3 summarizes ﬁndings from
conditional models regressing case-control status on cate-
gorized circulating 25(OH)D, additionally adjusted for
height. No association was observed between categories of
25(OH)D concentration and NHL risk (Ptrend ¼ 0.68). Anal-
yses of log(25(OH)D) as a continuous variable, 25(OH)D
categories using sex-/cohort-/season-speciﬁc cutpoints, and
categories of residuals of predicted 25(OH)D were similarly
null for overall models (Table 4).
In analyses stratiﬁed by sex, categories of 25(OH)D con-
centrationwerenot associatedwith NHL among men(Ptrend ¼
0.50), although the calculated odds ratio for men in
the  100 nmol/L (vs. 50–<75 nmol/L) category was sug-
gestive of an association with reduced risk (odds ratio ¼
0.65, 95% conﬁdence interval: 0.38, 1.11; Table 3). When
this category was further subdivided by using an a priori
cutpoint of 120 nmol/L, the inverse association was stronger
for the higher subcategory but was not statistically signiﬁ-
cant (100–<120 nmol/L: odds ratio ¼ 0.74, 95% conﬁdence
interval: 0.40, 1.36;  120 nmol/L: odds ratio ¼ 0.41, 95%
conﬁdence interval: 0.13, 1.29). However, no such ﬁndings
were observed among women (100–<120 nmol/L: odds ra-
tio ¼ 1.25, 95% conﬁdence interval: 0.60, 2.61;  120 nmol/
L: odds ratio ¼ 1.25, 95% conﬁdence interval: 0.43, 3.66).
In fact, there was suggestive evidence of a weak increased
risk of NHL with higher 25(OH)D among women from
analyses of continuous log(25(OH)), 25(OH)D categories
using sex-/cohort-/season-speciﬁc cutpoints, and residuals of
predicted 25(OH)D (Table 4).
Forest plots summarizing the statistically stable study-
speciﬁc odds ratios for <25 nmol/L and  100 nmol/L for
men and women are shown in Figure 1. In sensitivity anal-
yses excluding individual studies, in turn, from the pooled
analysis, the apparent association with 25(OH)D among
women weakened after excluding CLUE and the Cancer
Prevention Study II Nutrition Cohort and strengthened after
excluding the Nurses’ Health Study (results not shown).
Stratiﬁed analyses were performed to investigate whether
the association between circulating 25(OH)D concentration
and NHL risk differed across levels of other participant
characteristics; selected results are summarized in Table 5.
No association between 25(OH)D and NHL risk was ob-
served within study subgroups deﬁned by season of blood
draw, age at baseline, latitude of residence, length of follow-
up, hormone replacement therapy use, calcium supplemen-
tation, and physical activity (results for the last 3 stratiﬁed
analyses not shown). Results of analyses restricted to white
subjects and to US cohorts were similarly null. In an attempt
to replicate the previously reported inverse association be-
tween 25(OH)D and lymphoma risk observed in ATBC,
analyses were conducted restricted to men and to the ﬁrst
5 years of follow-up. No associations were observed in
these analyses (all studies, Ptrend ¼ 0.26; excluding ATBC,
Ptrend ¼ 0.63).
Table 4. Odds Ratios and 95% Conﬁdence Intervals for the Association Between Circulating 25(OH)D and Risk of Non-Hodgkin Lymphoma
Within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers: Results for Continuous 25(OH)D on a Log Scale, 25(OH)D Categories
Using Stratum-speciﬁc Cutpoints, and Categories of Residuals From Modeled 25(OH)D
Measure Quartile
Overall Men
a Women
a
No. of
Cases
No. of
Controls
b OR
c 95% CI No. of
Cases
No. of
Controls OR 95% CI No. of
Cases
No. of
Controls OR 95% CI
Log(25(OH)D):
per unit increase
1.03 0.86, 1.24 0.88 0.69, 1.13 1.27 0.96, 1.68
Sex-, cohort-, and season-
speciﬁc cutpoints
d 1 289 364 1.00 Referent 170 225 1.00 Referent 119 139 1.00 Referent
2 301 357 1.11 0.89, 1.39 176 235 1.04 0.78, 1.38 125 122 1.23 0.87, 1.76
3 335 367 1.19 0.95, 1.48 209 238 1.17 0.89, 1.56 126 129 1.20 0.84, 1.72
4 348 368 1.21 0.97, 1.51 178 225 1.07 0.80, 1.43 170 143 1.43 1.01, 2.02
Ptrend 0.08 0.49 0.06
Residuals from
modeled 25(OH)D
e 1 295 370 1.00 Referent 172 232 1.00 Referent 123 138 1.00 Referent
2 306 375 1.06 0.85, 1.33 186 240 1.07 0.81, 1.41 120 135 1.06 0.74, 1.52
3 332 342 1.24 1.00, 1.55 206 225 1.23 0.93, 1.63 126 117 1.27 0.88, 1.82
4 340 369 1.16 0.93, 1.45 169 226 1.01 0.75, 1.35 171 143 1.41 1.00, 2.00
Ptrend 0.09 0.66 0.03
Abbreviations: CI, conﬁdence interval; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
a Tests of interaction with sex were not statistically signiﬁcant.
b Doesnotincludesubjectswithmissingdata for modelcovariate(height).Alsodoesnotincludecontrolsmatchedto lymphomacasesotherthan
non-Hodgkin lymphoma, which were excluded from the analysis.
c Conditional models were adjusted for height ( 165, >165–171, >171–178, >178 cm).
d Cutpoints deﬁned as quartiles among all controls within a given stratum based on sex, cohort, and season of blood collection.
e Residuals from predicted circulating 25(OH)D computed by linear regression with adjustment for cohort, sex, and season of blood draw.
Cutpoints were deﬁned based on sex and cohort-speciﬁc quartiles among controls.
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Figure 1. Forest plots for the meta-analysis of the association between circulating 25-hydroxyvitamin D (25(OH)D) and the risk of non-Hodgkin lymphoma within the Cohort Consortium
Vitamin D Pooling Project of Rarer Cancers. Risk estimates, by cohort, for subjects with circulating 25(OH)D concentrations of <25 nmol/L and  100 nmol/L compared with the referent group
(50–<75 nmol/L). Results for <25 nmol/Lfor A)men and B) women; results for  100 nmol/L for C) men and D) women.Odds ratios (ORs; boxes) and 95% conﬁdence intervals (CIs; bars) were
derived from conditional logistic regression models adjusted for height. The size of each box is inversely proportional to the variance of the log odds ratio estimate in each cohort. The overall
estimates (diamonds) were derived from a meta-analysis using random-effects modeling. Data from some cohorts are missing from some forest plots—A): Nurses’ Health Study (NHS), New
York University Women’s Health Study (NYU-WHS), Shanghai Women’s Health Study (SWHS); B): Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), Health Professionals
Follow-up Study (HPFS), Shanghai Men’s Health Study (SMHS); C): NHS, NYU-WHS, SWHS; D): ATBC, HPFS, SMHS—because they are sex-speciﬁc or have unstable risk estimates due to
small numbers. CPS-II, Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
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9Table 5. Odds Ratios and 95% Conﬁdence Intervals for the Association Between Circulating 25(OH)D and Risk of Non-Hodgkin Lymphoma Within the Cohort Consortium Vitamin D Pooling
Project of Rarer Cancers: Results From Analyses Stratiﬁed by Selected Study and Subject Characteristics
a
Stratiﬁcation Factor No. of
Cases
No. of
Controls
Circulating 25(OH)D, nmol/L (Categorized by Using a Priori Cutpoints)
Ptrend <25 25–<37.5 37.5–<50 50–<75 75–<100 ‡100
OR
b 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Season of blood draw
c
December–May 573 836 0.97 0.66, 1.42 0.82 0.59, 1.13 0.90 0.67, 1.20 1.00 Referent 0.83 0.57, 1.23 0.79 0.38, 1.61 0.94
June–November 689 831 1.59 0.91, 2.76 0.96 0.66, 1.39 1.05 0.79, 1.40 1.00 Referent 1.41 1.06, 1.89 0.86 0.54, 1.37 0.90
Age, years
c
 60 508 767 1.28 0.81, 2.03 0.80 0.55, 1.17 0.95 0.69, 1.31 1.00 Referent 1.30 0.91, 1.85 0.96 0.52, 1.76 0.47
>60 754 900 1.08 0.71, 1.63 0.98 0.71, 1.36 1.01 0.78, 1.32 1.00 Referent 1.06 0.78, 1.44 0.73 0.44, 1.20 0.61
Restricted to Caucasians 1,100 1,464 1.31 0.91, 1.89 0.93 0.71, 1.22 0.93 0.74, 1.16 1.00 Referent 1.19 0.93, 1.53 0.78 0.51, 1.19 0.93
Restricted to US cohorts 1,104 1,183 1.16 0.77, 1.74 0.83 0.61, 1.13 0.90 0.71, 1.15 1.00 Referent 1.21 0.93, 1.58 0.94 0.61, 1.45 0.27
Latitude ( N)
c
<35 225 262 0.60 0.29, 1.24 0.66 0.35, 1.24 1.15 0.68, 1.96 1.00 Referent 0.99 0.57, 1.73 1.22 0.52, 2.89 0.13
35–42 600 595 1.74 1.03, 2.94 1.10 0.74, 1.62 0.96 0.70, 1.32 1.00 Referent 1.50 1.08, 2.09 0.99 0.55, 1.77 0.95
>42 437 811 1.06 0.66, 1.69 0.80 0.55, 1.15 0.91 0.67, 1.25 1.00 Referent 0.83 0.55, 1.24 0.52 0.25, 1.07 0.55
Follow-up time to
case diagnosis, years
c
 5 634 767 1.04 0.66, 1.64 0.76 0.52, 1.10 1.03 0.76, 1.40 1.00 Referent 1.02 0.72, 1.42 0.86 0.51, 1.43 0.71
>5 628 895 1.12 0.69, 1.80 1.09 0.77, 1.54 0.94 0.70, 1.26 1.00 Referent 1.32 0.94, 1.85 0.84 0.44, 1.59 0.82
NHL subtype
DLBCL 306 1,667 1.27 0.76, 2.12 0.87 0.57, 1.32 1.05 0.76, 1.47 1.00 Referent 0.94 0.64, 1.38 0.74 0.39, 1.42 0.40
FL 194 1,667 0.91 0.44, 1.92 0.72 0.41, 1.25 1.26 0.86, 1.86 1.00 Referent 1.18 0.76, 1.82 0.49 0.19, 1.26 0.98
CLL/SLL 379 1,667 1.11 0.70, 1.78 0.86 0.59, 1.25 0.76 0.55, 1.05 1.00 Referent 1.41 1.02, 1.95 0.56 0.28, 1.12 0.33
Other/NOS 383 1,667 1.28 0.82, 1.98 1.07 0.75, 1.54 1.04 0.76, 1.42 1.00 Referent 1.09 0.76, 1.56 1.39 0.83, 2.34 0.92
Abbreviations: CI, conﬁdence interval; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; NHL, non-
Hodgkin lymphoma; NOS, not otherwise speciﬁed; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
a Does not include subjects with missing data for model covariate (height). Includes controls matched to lymphoma cases other than non-Hodgkin lymphoma, which were excluded from the
analysis.
b Odds ratios for subject strata were computed by using unconditional logistic regression adjusting for height ( 165, >165–171, >171–178, >178 cm). Odds ratios for restricted analyses
(Caucasians, US cohorts) and follow-up time to diagnosis strata were computed by using conditional logistic regression adjusting for height. Odds ratios for histologic subtypes were computed
by using polytomous regression adjusting for height.
c Tests of interaction with each stratiﬁcation factor were not statistically signiﬁcant.
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histologic subtypes of NHL and 25(OH)D was observed
(Table 5). Odds ratio estimates for follicular lymphoma
and CLL/SLL in individuals with a concentration of  100
nmol/L (vs. 50–<75 nmol/L) were 0.49 and 0.56, respec-
tively, although the corresponding 95% conﬁdence intervals
included the null value and trend tests were negative. When
this category was subdivided by using the a priori cutpoint
of 120 nmol/L, the apparent inverse association with follic-
ular lymphoma became stronger with increasing 25(OH)D
but was not statistically signiﬁcant (100–<120 nmol/L:
odds ratio ¼ 0.55, 95% conﬁdence interval: 0.19,
1.57;  120 nmol/L: odds ratio ¼ 0.35, 95% conﬁdence
interval: 0.05, 2.67). There were no cases of CLL/SLL with
a 25(OH)D concentration of  120 nmol/L. The odds ratios
for DLBCL were observed to change with increasing
25(OH)D in a pattern generally consistent with a dose-
response relation, although the test for trend was not statis-
tically signiﬁcant (P ¼ 0.40).
DISCUSSION
On the basis of several case-control ﬁndings suggesting
an inverse association between sun exposure and NHL, it
was hypothesized that the vitamin D pathway may be pro-
tective against lymphomagenesis. However, in this pooled
analysis involving serum or plasma specimens from 10 co-
hort studies, there was no clear evidence of an association
between circulating concentrations of the vitamin D metab-
olite 25(OH)D and risk of NHL.
The only previous study known to have directly investi-
gated circulating 25(OH)D and NHL, which was conducted
within the ATBC cohort of male Finnish smokers, also
found no association overall (23). However, the investiga-
tors noted a statistically signiﬁcant inverse association
with risk within the ﬁrst 7 years of follow-up. Among cases
diagnosed after 7 years of follow-up, a non-statistically-
signiﬁcant increased risk with increasing serum 25(OH)D
was observed. In this pooled analysis, which included the
ATBC data, we observed no overall evidence of association
among men. A non-statistically-signiﬁcant association with
reduced risk was observed among men at very high levels of
25(OH)D; however, no such ﬁnding was observed among
women or among measures of 25(OH)D that used alternate
methods to deal with the inﬂuence of season of blood col-
lection. Results of analyses of men restricted to the ﬁrst 5
years of follow-up, both including and excluding the ATBC
subjects, were similarly null. The totality of the evidence
from this pooled analysis thus does not support an associa-
tion with 25(OH)D among men or within an earlier period of
follow-up from blood collection.
The ﬁndings among women, suggestive of a weak in-
creased risk of NHL with increasing 25(OH)D, were unex-
pected. In an analysis investigating correlates of 25(OH)D
among VDPP controls, women were observed to have sig-
niﬁcantly lower levels than men did; the median 25(OH)D
concentrations in men and women in the United States were
58.4 nmol/L and 51.7 nmol/L, and those in China were 38.0
nmol/L and 33.1 nmol/L, respectively (30). Interestingly,
one population-based case-control study of NHL conducted
among women in Connecticut observed a statistically sig-
niﬁcant increased risk with increasing sun exposure (15).
However, analyses of recreational sun exposure and NHL
risk restricted to women in the International Lymphoma
Epidemiology (InterLymph) Consortium pooled analysis
suggested a weak inverse association with increasing recre-
ational sun exposure and no associationwith total ultraviolet
radiation exposure. We are unaware of any biologic ratio-
nale for vitamin D to have an adverse effect on NHL risk for
women, but not men. It is possible that these ﬁndings may
have arisen because of chance.
Analyses by the common histologic subtypes of NHL
generally did not show an association with 25(OH)D. Al-
though individuals with the highest concentrations of
25(OH)D were at lower risk of DLBCL, follicular lym-
phoma, and CLL/SLL, the individual estimates and tests
for trends were not statistically signiﬁcant. The published
epidemiologic evidence regarding vitamin D and NHL
subtypes is extremely limited. In a previously published
investigation within ATBC, the investigators observed an
inverse association between 25(OH)D concentration and
CLL/SLL risk, whereas ﬁndings for follicular lymphoma
or diffuse lymphoma were null (23). Recent NHL case-
control studies that have reported inverse associations with
sun exposure have generally not discovered different ﬁnd-
ings across B-cell subtypes (16). However, in one study,
the estimated association between sun exposure and fol-
licular lymphoma was found to vary across genotypes of
the vitamin D receptor gene polymorphism TaqI (31).
Given the evidence in hand and the limited study power
to detect subtype-speciﬁc associations, the ﬁndings from
this study for follicular lymphoma, DLBCL, and CLL/SLL
are inconclusive.
An important strength of this study is its sample size; with
more than 1,300 cases, it is one of the largest prospective,
biospecimen-based investigations of NHL conducted to
date. Another strength is the broad variation in measured
25(OH)D concentrations, at least partly due to the broad
range in latitude covered by the participating cohorts. The
study also beneﬁted from having specimens from all 10 of
the cohorts measured at the same laboratory and, excepting
ATBC, at the same time.
A limitation of this study, shared by virtually all prospec-
tive investigations of vitamin D metabolites and cancer risk,
is its reliance upon a single measurement of 25(OH)D as
a surrogate for long-term vitamin D status. The long-term
intraindividual variation in circulating 25(OH)D is unclear,
although, in one study of 144 men with 2 blood specimens
collected 3–4 years apart, the correlation between the 2
plasma25(OH)Dmeasurementswasfairlyhigh,withaPear-
son correlation coefﬁcient of 0.70 (32). Nonetheless, the
possibility remains that these single measurements did not
adequately capture long-term 25(OH)D levels, and a real
association with vitamin D may have been missed. Lastly,
although the numbers of follicular lymphoma, DLBCL, and
CLL/SLL cases in this study were relatively high compared
with other studies of NHL, statistical power to detect
subtype-speciﬁc associations of moderate magnitude was
limited.
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dence from this pooled analysis does not support the hypoth-
esis that circulating 25(OH)D concentration is associated
with reduced NHL risk. In view of these ﬁndings, it seems
unlikely that the weak inverse association between sun ex-
posure and NHL risk reported by recent case-control studies
is mediated by the vitamin D pathway alone. Assuming that
the association between sun exposure and NHL is real and
not simply the product of confounding from other lifestyle
factors, other possible mechanisms for this association must
be considered. One such possibility is ultraviolet radia-
tion–induced immune modulation. Exposure to ultraviolet
radiation depresses T-helper 1–mediated immune re-
sponses and enhances T-helper 2–mediated immune activ-
ity, both locally and systemically (33–35). Several studies
have reported lower NHL risks for people with allergic
conditions (proposed markers of a dominant T-helper 2
immune response; summarized by Grulich et al. (36))
and have led to the suggestion that a T-helper 2–dominated
immune response may be associated with a reduced risk of
NHL (36). Additional research investigating ultraviolet
radiation–induced immunologic effects and other hypoth-
eses addressing the biologic basis for the sunlight–NHL
association is needed.
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